Pipeline

A pipeline innovated by the global human crisis

Indivior is pioneering the development and discovery of non-opioid treatment strategies for OUD, as well as exploring new therapies to potentially address the needs of people suffering from alcohol, stimulant and cannabis use disorders. 

Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder. We also developed a monthly treatment option for the treatment of schizophrenia in adult patients. 

Indivior’s quarterly R&D and pipeline update can be found here.

 

Compound Name

Preclinical

Phase 1

Phase 2

Phase 3

Regulatory Approval or Review

 
 
 
 
 
 
  • Treatment for Substance Use Disorder

    INDV-3000 - Selective Dopamine D3-receptor Antagonist

  • Treatment for Substance Use Disorder

    INDV-10001 - GABA-B Positive Allosteric Modulator

  • Treatment for Substance Use Disorder

    INDV-20002 - Selective Orexin-1 Receptor Antagonist

  • Treatment for Cannabis Use Disorder

    AEF01173 - Synthetic Signaling Specific inhibitor (SSi) of the Cannabinoid Type 1 (CB1) Receptor

  • Treatment for Opioid Use Disorder

    RBP-6000 - Buprenorphine XR injection for Subcutaneous Use

  • Treatment for Schizophrenia

    RBP-70004 - Risperidone XR injection for Subcutaneous Use

  • Treatment for Opioid Use Disorder

    Buprenorphine/ Naloxone Sublingual Film

  • Treatment for Opioid Use Disorder

    Buprenorphine/ Naloxone Sublingual Tablet

  • Treatment for Opioid Use Disorder

    Buprenorphine Sublingual Tablet

Pipeline Disclaimer: The information included on this site reflects Indivior’s research and development pipeline and is not intended for promotional purposes. Information is current as of July 30, 2021.